The Prescription Drug User Fee Act (PDUFA) was created by Congress in 1992 and authorizes FDA to collect fees from companies that produce certain human drug and biological products. Since the passage of PDUFA, user fees have played an important role in expediting the drug approval process.
Similar Posts
FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live): FDA Safety Communication
FDA Update on the Safety of Ixchiq (Chikungunya Vaccine, Live). FDA Removes Recommended Pause in Use and Approves Required Updated Labeling: FDA Safety CommunicationMatrixx Initiatives Inc. (Zicam), Scottsdale, AZ 483 issued 5/28/2009 (1 page)
Matrixx Initiatives Inc. (Zicam), Scottsdale, AZ 483 issued 5/28/2009 (1 page)Activities Report of the Generic Drug Program | FDARA Title VIII Sections 807 and 805
Section 807 of the FDA Reauthorization Act of 2017 (FDARA) requires the FDA to report on certain abbreviated new drug applications (ANDAs).Pharmacy Compounding Advisory Committee Roster
This page contains the PCAC roster, which lists the current members and the current number of vacancies for the committee.Study Data Technical Conformance Guide – Technical Specifications Document
This technical specifications document represents the Food and Drug Administration’s (FDA’s) current thinking on this topic.Kuka Flex Forte contains hidden drug ingredient
The Food and Drug Administration is advising consumers not to purchase or use Kuka Flex Forte, a product promoted and sold for joint pain and arthritis on various websites, including https://botanical-be.com, and possibly in some retail stores.